<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489918</url>
  </required_header>
  <id_info>
    <org_study_id>CP-2006-001</org_study_id>
    <nct_id>NCT00489918</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis</brief_title>
  <official_title>A Dose Ranging Study of the Effects of Macroflux® PTH Compared With Macroflux® Placebo and FORTEO® in Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zosano Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zosano Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-center study to determine effects of various doses of Macroflux Parathryroid Hormone
      (PTH) in women with osteoporosis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percent Change in Lumbar Spine Bone Mineral Density (BMD) from Baseline to Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Lumbar Spine Bone Mineral Density: Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent Change in Lumbar Spine Bone Mineral Density from Baseline to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Lumbar Spine BMD: Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Absolute Change in Lumbar Spine BMD from Baseline to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Hip Bone Mineral Density: Baseline to Week 24</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Percent Change in Total Hip Bone Mineral Density from Baseline to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Femoral Neck BMD: Baseline to Week 24</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Percent Change in Femoral Neck BMD from Baseline to Week 24</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Macroflux® placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Macroflux® placebo patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Macroflux® 20 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Macroflux® 20 mcg patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Macroflux® 30 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Macroflux® 30 mcg patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Macroflux® 40 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Macroflux® 40 mcg patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FORTEO®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FORTEO® 20 mcg injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teriparatide</intervention_name>
    <description>Macroflux® patch applied to the abdomen for 30 minutes daily</description>
    <arm_group_label>Macroflux® 20 mcg</arm_group_label>
    <arm_group_label>Macroflux® 30 mcg</arm_group_label>
    <arm_group_label>Macroflux® 40 mcg</arm_group_label>
    <arm_group_label>Macroflux® placebo</arm_group_label>
    <other_name>PTH(1-34)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teriparatide</intervention_name>
    <description>FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh</description>
    <arm_group_label>FORTEO®</arm_group_label>
    <other_name>FORTEO®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy postmenopausal women age 50 years or older

          -  At least three lumbar vertebrae (L1-L4) must be evaluable by dual energy x-ray
             absorptiometry (DXA) for bone mineral densitometry that is, without fracture or
             significant degenerative disease, as determined by the central imaging facility

          -  Have osteoporosis defined as: Either a T-score of ≤ -2.5 at the lumbar spine, femoral
             neck, or total hip, AND a T-score of at least &lt; -1.0 at the lumbar spine; or A T-score
             of ≤ -2.0 at the lumbar spine, femoral neck, or total hip, AND at least one vertebral
             fracture;

        Exclusion Criteria:

          -  Active hepatitis;

          -  Active pancreatitis;

          -  Unstable cardiac disease;

          -  Unstable pulmonary disease;

          -  Celiac disease;

          -  Hyper- or hypo-parathyroidism;

          -  Hyperthyroidism;

          -  Cushing's disease;

          -  Osteomalacia;

          -  Paget's disease;

          -  Osteogenesis imperfecta;

          -  Known blood disorders;

          -  History of kidney stones;

          -  Impaired renal function;

          -  Autoimmune diseases;

          -  Bone metastases or a history of skeletal malignancies;

          -  Cancer history that includes any cancer within the previous 5 years, with the
             exception of squamous or basal cell carcinoma of the skin in which the lesions were
             fully resected with clear margins described in a written report by a pathologist, and
             the patient has had no recurrence of lesions for at least 1 year from the time of
             original resection;

          -  Any condition or disease that may interfere with the ability to have or the evaluation
             of a DXA scan, for example, severe osteoarthritis of the spine, spinal fusion, pedicle
             screws, history of vertebroplasty, or degenerative disease that results in
             insufficient number of evaluable lumbar vertebrae, or &gt;1 lumbar vertebral fracture in
             L1-L4;

          -  More than 4 vertebral fractures in T4-L4;

          -  Bilateral hip replacements;

          -  Use of fluoride (e.g. fluoride therapy for osteoporosis) or strontium at any time;

          -  Have received methotrexate or immunomodulatory agents with antiproliferative activity;

          -  With known dermatological disorders that would interfere with the study procedures or
             assessments, or with a history of contact dermatitis;

          -  With known allergy or sensitivity to tapes, adhesives, PTH, teriparatide or its
             analogs, or components of the Macroflux® systems;

          -  Who, in the opinion of the investigator, should not participate in the study, or may
             not be capable of following the study schedule for any reason; and

          -  Unwillingness or inability to abide by the requirements of the study.

          -  Have received any intravenous (IV) administered bisphosphonates in the past 24 months,
             or &gt;2 doses of IV administered bisphosphonates total;

          -  Use of oral bisphosphonates before randomization, including investigational
             bisphosphonates, unless: &lt;6 months of treatment and off for 6 months, or 6-12 months
             of treatment and off for 2 years, or &gt;12 months of treatment and off for 5 years;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thorsten von Stein, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Zosano Pharma Corporation</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 19, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <results_first_submitted>September 26, 2016</results_first_submitted>
  <results_first_submitted_qc>July 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2018</results_first_posted>
  <last_update_submitted>July 3, 2018</last_update_submitted>
  <last_update_submitted_qc>July 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Macroflux® Placebo</title>
          <description>Macroflux® placebo patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
        </group>
        <group group_id="P2">
          <title>Macroflux® 20 mcg</title>
          <description>Macroflux® 20 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
        </group>
        <group group_id="P3">
          <title>Macroflux® 30 mcg</title>
          <description>Macroflux® 30 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
        </group>
        <group group_id="P4">
          <title>Macroflux® 40 mcg</title>
          <description>Macroflux® 40 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
        </group>
        <group group_id="P5">
          <title>FORTEO®</title>
          <description>FORTEO® 20 mcg injection
teriparatide: FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Postmenopausal women with osteoporosis</population>
      <group_list>
        <group group_id="B1">
          <title>Macroflux® Placebo</title>
          <description>Macroflux® placebo patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
        </group>
        <group group_id="B2">
          <title>Macroflux® 20 mcg</title>
          <description>Macroflux® 20 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
        </group>
        <group group_id="B3">
          <title>Macroflux® 30 mcg</title>
          <description>Macroflux® 30 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
        </group>
        <group group_id="B4">
          <title>Macroflux® 40 mcg</title>
          <description>Macroflux® 40 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
        </group>
        <group group_id="B5">
          <title>FORTEO®</title>
          <description>FORTEO® 20 mcg injection
teriparatide: FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="33"/>
            <count group_id="B5" value="33"/>
            <count group_id="B6" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="7.1"/>
                    <measurement group_id="B2" value="64.1" spread="7.5"/>
                    <measurement group_id="B3" value="63.6" spread="5.8"/>
                    <measurement group_id="B4" value="64.6" spread="7.3"/>
                    <measurement group_id="B5" value="63.2" spread="6.8"/>
                    <measurement group_id="B6" value="64.06" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24</title>
        <description>Percent Change in Lumbar Spine Bone Mineral Density (BMD) from Baseline to Week 24</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent to treat (ITT)/Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Macroflux® Placebo</title>
            <description>Macroflux® placebo patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O2">
            <title>Macroflux® 20 mcg</title>
            <description>Macroflux® 20 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O3">
            <title>Macroflux® 30 mcg</title>
            <description>Macroflux® 30 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O4">
            <title>Macroflux® 40 mcg</title>
            <description>Macroflux® 40 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O5">
            <title>FORTEO®</title>
            <description>FORTEO® 20 mcg injection
teriparatide: FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24</title>
          <description>Percent Change in Lumbar Spine Bone Mineral Density (BMD) from Baseline to Week 24</description>
          <population>Intent to treat (ITT)/Safety Population</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="3.467"/>
                    <measurement group_id="O2" value="2.96" spread="3.524"/>
                    <measurement group_id="O3" value="3.47" spread="3.575"/>
                    <measurement group_id="O4" value="4.97" spread="4.114"/>
                    <measurement group_id="O5" value="3.55" spread="3.730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Lumbar Spine Bone Mineral Density: Baseline to Week 12</title>
        <description>Percent Change in Lumbar Spine Bone Mineral Density from Baseline to Week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>ITT/Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Macroflux® Placebo</title>
            <description>Macroflux® placebo patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O2">
            <title>Macroflux® 20 mcg</title>
            <description>Macroflux® 20 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O3">
            <title>Macroflux® 30 mcg</title>
            <description>Macroflux® 30 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O4">
            <title>Macroflux® 40 mcg</title>
            <description>Macroflux® 40 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O5">
            <title>FORTEO®</title>
            <description>FORTEO® 20 mcg injection
teriparatide: FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Lumbar Spine Bone Mineral Density: Baseline to Week 12</title>
          <description>Percent Change in Lumbar Spine Bone Mineral Density from Baseline to Week 12</description>
          <population>ITT/Safety Population</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="3.312"/>
                    <measurement group_id="O2" value="1.55" spread="2.606"/>
                    <measurement group_id="O3" value="2.04" spread="3.277"/>
                    <measurement group_id="O4" value="2.5" spread="2.86"/>
                    <measurement group_id="O5" value="2.81" spread="2.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Lumbar Spine BMD: Baseline to Week 12</title>
        <description>Absolute Change in Lumbar Spine BMD from Baseline to Week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>ITT/Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Macroflux® Placebo</title>
            <description>Macroflux® placebo patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O2">
            <title>Macroflux® 20 mcg</title>
            <description>Macroflux® 20 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O3">
            <title>Macroflux® 30 mcg</title>
            <description>Macroflux® 30 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O4">
            <title>Macroflux® 40 mcg</title>
            <description>Macroflux® 40 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O5">
            <title>FORTEO®</title>
            <description>FORTEO® 20 mcg injection
teriparatide: FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Lumbar Spine BMD: Baseline to Week 12</title>
          <description>Absolute Change in Lumbar Spine BMD from Baseline to Week 12</description>
          <population>ITT/Safety Population</population>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.0234"/>
                    <measurement group_id="O2" value="0.011" spread="0.0191"/>
                    <measurement group_id="O3" value="0.014" spread="0.0238"/>
                    <measurement group_id="O4" value="0.017" spread="0.0285"/>
                    <measurement group_id="O5" value="0.021" spread="0.0201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Hip Bone Mineral Density: Baseline to Week 24</title>
        <description>Percent Change in Total Hip Bone Mineral Density from Baseline to Week 24</description>
        <time_frame>24 Weeks</time_frame>
        <population>ITT/Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Macroflux® Placebo</title>
            <description>Macroflux® placebo patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O2">
            <title>Macroflux® 20 mcg</title>
            <description>Macroflux® 20 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O3">
            <title>Macroflux® 30 mcg</title>
            <description>Macroflux® 30 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O4">
            <title>Macroflux® 40 mcg</title>
            <description>Macroflux® 40 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O5">
            <title>FORTEO®</title>
            <description>FORTEO® 20 mcg injection
teriparatide: FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Hip Bone Mineral Density: Baseline to Week 24</title>
          <description>Percent Change in Total Hip Bone Mineral Density from Baseline to Week 24</description>
          <population>ITT/Safety Population</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.634" spread="1.9719"/>
                    <measurement group_id="O2" value="0.138" spread="2.0386"/>
                    <measurement group_id="O3" value="0.553" spread="2.3694"/>
                    <measurement group_id="O4" value="1.331" spread="2.1111"/>
                    <measurement group_id="O5" value="0.094" spread="2.6194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Femoral Neck BMD: Baseline to Week 24</title>
        <description>Percent Change in Femoral Neck BMD from Baseline to Week 24</description>
        <time_frame>24 Weeks</time_frame>
        <population>ITT/Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Macroflux® Placebo</title>
            <description>Macroflux® placebo patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O2">
            <title>Macroflux® 20 mcg</title>
            <description>Macroflux® 20 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O3">
            <title>Macroflux® 30 mcg</title>
            <description>Macroflux® 30 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O4">
            <title>Macroflux® 40 mcg</title>
            <description>Macroflux® 40 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
          </group>
          <group group_id="O5">
            <title>FORTEO®</title>
            <description>FORTEO® 20 mcg injection
teriparatide: FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Femoral Neck BMD: Baseline to Week 24</title>
          <description>Percent Change in Femoral Neck BMD from Baseline to Week 24</description>
          <population>ITT/Safety Population</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.172" spread="3.3432"/>
                    <measurement group_id="O2" value="0.949" spread="3.2975"/>
                    <measurement group_id="O3" value="0.599" spread="2.6127"/>
                    <measurement group_id="O4" value="0.750" spread="2.6132"/>
                    <measurement group_id="O5" value="-0.012" spread="3.6600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Macroflux® Placebo</title>
          <description>Macroflux® placebo patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
        </group>
        <group group_id="E2">
          <title>Macroflux® 20 mcg</title>
          <description>Macroflux® 20 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
        </group>
        <group group_id="E3">
          <title>Macroflux® 30 mcg</title>
          <description>Macroflux® 30 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
        </group>
        <group group_id="E4">
          <title>Macroflux® 40 mcg</title>
          <description>Macroflux® 40 mcg patch
teriparatide: Macroflux® patch applied to the abdomen for 30 minutes daily</description>
        </group>
        <group group_id="E5">
          <title>FORTEO®</title>
          <description>FORTEO® 20 mcg injection
teriparatide: FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <description>Dehydration due to gastroenterocolitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalciuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Application site discolorations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Application site bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Application site bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Application site edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Don Kellerman, VP of Clinical Development and Medical Affairs</name_or_title>
      <organization>Zosano Pharma Inc.</organization>
      <phone>(510) 745-4004</phone>
      <email>dkellerman@zosanopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

